Weifa ASA is pleased to announce the launch of Zonat® tablets, which is indicated for short-term symptomatic treatment of occasional insomnia in adults over 18 years old. Zonat® contains the antihistamine doxylamine, which is well established as a non-prescription (OTC) product for occasional insomnia in several European countries. In Norway Zonat® will require medical prescription.

Zonat® is in licensed from the pharmaceutical company Esteve, located in Spain, which is one of Weifa's international collaboration  partners. 

Zonat® exerts potent hypnotic action and is effective in decreasing sleep onset latency and in increasing the depth of sleep and its duration.

"With Zonat® Weifa enters a new therapeutic category, insomnia. This launch is a result of Weifa's long-term strategy to broaden Weifa's core business with products in selected new categories where we see medical needs and marketing opportunities. Our ambition is to contribute significantly to the future growth of this category ", says CEO Kathrine Gamborg Andreassen.

The market value of medical prescription products for insomnia in Norway increased by 10% and amounted to mnok 138 (pharmacy purchasing price) in 20151.

 Zonat® tablets in two strengths, 12,5 mg and 25 mg, will be available on the Norwegian market  from mid-august 2016.

For further information, please contact:

Kathrine Gamborg Andreassen

CEO

+47 95 17 86 80, kathrine.gamborg.andreassen@weifa.no

Simen Nyberg-Hansen

CFO

+47 98 20 63 55, simen.nyberg-hansen@weifa.no

Weifa is Norway's leading consumer health company. We supply real value through medicines, lifestyle products and solutions that address the essential needs of consumers, customers and professional partners. Weifa was founded in 1940 and now employs about 30 highly qualified people at our headquarters in Oslo. The company has a strong position in Norway and is the market leader in pain relief, with well-established brands such as Paracet and Ibux. We are also present in other key areas such as dietary supplements and treatment for colds and respiratory problems. Weifa is listed on the Oslo Børs (ticker WEIFA). For further information, please visit: www.weifa.no

Ref: 1. Farmastat 2015